Ann: Updated Corporate Presentation, page-17

Hi everyone,

I hope this message finds you well.

I wanted to share my current understanding of Alterity’s progress with the FDA and what we might expect moving forward.

It’s my belief that Alterity will be holding their initial meeting with the FDA in the very near term. This will likely be the first of several meetings, with the final one anticipated to take place in the fourth quarter of the year. If all goes according to plan, Management believes this final meeting could result in the FDA granting Accelerated Approval.

At present, major pharmaceutical companies appear to be observing from the sidelines, awaiting the outcome of these meetings. From what I understand, some of these companies have already expressed to Management that they would be willing to pay a premium to partner with Alterity, contingent on receiving the appropriate FDA approvals.

That said, we may see offers begin to surface even earlier. Smaller companies, unable to compete with the larger players, might decide to act quickly following the initial FDA meetings. Some of these organizations may be comfortable making early moves based on informal feedback from the FDA regarding next steps.

I’m confident that meeting minutes will be recorded and shared with parties who have a strong interest in Alterity’s future. One thing is certain—there are many companies watching our progress closely.

Please don’t be discouraged by our current share price. Like many of you, I’d like to see it trading above 10 cents, especially given the progress we’ve made. While that’s not yet the case, patience is key. We are very close to a pivotal moment. By the end of this quarter, we should have a clearer picture of where we stand.

Once the team has met with the FDA, they will be able to publicly share the outcome and sentiment of that meeting, which could serve as a significant catalyst for the share price.

Financially, we’re in a strong position. We have substantial cash reserves and a low burn rate, so a capital raise is not currently on the agenda. Dr. Stamler and the team continue to manage resources conservatively, and I believe we are in very capable hands.

From here, anything is possible—expect the unexpected. My advice to fellow shareholders is simple: hang in there. We’ve come a long way, and I truly believe we’re on the brink of something transformative.

For everyone in Australia, enjoy the long weekend!

Good luck to all holders,
Stockman